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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA)
has become the dominant strain of Staphylococcus
aureus in many communities of the United States.
As a result, many clinicians are now empirically
covering for this pathogen in the treatment of
various skin and soft-tissue infections. Should this
practice apply to cellulitis? In order to answer this
question, we defined cellulitis and reviewed the
pathogenesis, microbiology, and current studies
of inpatient and outpatient antimicrobial
therapy. The current evidence suggests empirical
MRSA coverage for community-acquired cellulitis
may not be necessary in non-purulent
(non-suppurative) forms of this infection. Most
cases are non-purulent and not amenable to
culture although antibody studies indicate
streptococci are the most common etiologic
agents. Current studies of antimicrobial therapy
tend to agree with this finding. Empirical beta-
lactam therapy directed primarily at streptococci
appears sufficient for non-purulent cellulitis
regardless of the prevalence of MRSA in the
community.
Keywords: Antibiotic; Cellulitis; Infectious
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INTRODUCTION
In what situations or under what circumstances
should coverage for community-acquired
methicillin-resistant Staphylococcus aureus
(CAMRSA) be included in empirical regimens
for cellulitis? Published guidelines offer
different recommendations. In addition, there
are differences in definitions for cellulitis. We
will review what has been published since the
2005 Infectious Diseases Society of America
(IDSA) guideline.
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The 2013 Sanford guide recommends only
empirical streptococcal coverage for cellulitis of
the extremities in non-diabetics [1]. MRSA
coverage is recommended only for severe
disease in diabetics and facial cellulitis. The
Johns Hopkins ABX Guide generally concurs
with the Sanford guide in emphasizing anti-
streptococcal coverage but recommends MRSA
coverage for hospitalized patients (intravenous
clindamycin, vancomycin, linezolid,
daptomycin, ceftaroline, or telavancin)
regardless of the presence of diabetes [2].
The IDSA guideline for erysipelas or cellulitis
recommends ‘‘dicloxacillin, cephalexin,
clindamycin, or erythromycin, unless
streptococci or staphylococci resistant to these
agents are common in the community’’ [3]. The
IDSA guidelines were published in 2005 and an
update will not be ready until late 2013 [4].
The more recent (published 2011) IDSA
guidelines for MRSA recommend empirical
(MRSA) coverage only for purulent cellulitis
[5]. In 2007, the Centers for Disease Control
published similar guidelines for skin and soft-
tissue infections that included endorsement by
IDSA and the American Medical Association [6].
Empirical MRSA coverage for non-purulent
cellulitis is not recommended unless a
therapeutic failure has occurred. These
guidelines also suggest that empirical (MRSA)
coverage for complicated skin and soft-tissue
infections be considered in hospitalized
patients.
MRSA has become common in the United
States and is more prevalent than methicillin-
sensitive Staphylococcus aureus (MSSA) in many
communities [7]. Many, if not most physicians,
routinely cover for MRSA using trimethoprim/
sulfamethoxazole (TMP/SMX), clindamycin,
doxycycline or fluoroquinolones in patients
with cellulitis [8]. Some authors advocate
empirical coverage of cellulitis when the skin
is intact [9]. Others suggest that empirical
therapy for CAMRSA be limited to seriously ill
patients or those who have failed initial
empirical therapy [10]. Still others recommend
such coverage when the community prevalence
is high, such as greater than 10–15% [7, 11]. Is
that appropriate in 2013? Should diabetics with
cellulitis always receive empirical coverage for
MRSA?
METHODS
PubMed was searched for the terms ‘‘cellulitis,’’
‘‘MRSA,’’ ‘‘skin and soft tissue infection,’’
‘‘community acquired staphylococcus’’ and
combinations of these terms during the
month of May, 2013. The results were
narrowed by omitting articles not in English
and those with terms including ophthalmic,
systemic, case studies, hospitalized, and
purulent. Additional articles were added in
October as a result of reviewer’s comments.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
WHAT IS CELLULITIS?
What is and what is not cellulitis is important in
determining a possible microbiological etiology
and treatment. Unfortunately, cellulitis is often
used to describe a broad group of superficially
similar (e.g., diffuse and spreading) but often
histologically distinct skin infections. The
International Classification of Diseases version
9 (ICD-9) creates further confusion by
combining cellulitis and abscess under a single
code [12].
Cellulitis, as defined in the 2005 IDSA skin
and soft-tissue infection guideline, is a diffuse
176 Infect Dis Ther (2013) 2:175–185
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spreading infection with inflammation of the
deeper dermis and subcutaneous fat. It excludes
‘‘infections associated with underlying
suppurative foci, such as cutaneous abscesses,
necrotizing fasciitis, septic arthritis, and
osteomyelitis’’ [3]. This definition is largely
histologic and excludes underlying
complicating or complex lesions. It delineates
cellulitis as the primary focus of infection and
not one resulting from contiguous extension.
This definition does not, however, exclude the
possibility of suppurative complications from
cellulitis.
Cellulitis is characterized by rapidly
spreading areas of edema, redness, and heat,
sometimes accompanied by lymphangitis and
inflammation of the regional lymph nodes.
Other manifestations such as vesicles, bullae,
and petechiae or ecchymoses may develop on
the inflamed skin. The affected integument may
eventually develop a pitting orange peel
appearance. Systemic manifestations are
usually mild, but fever, tachycardia, confusion,
hypotension, and leukocytosis may be present
and occur hours before the skin abnormalities
appear. Vesicles and bullae filled with clear fluid
are common. The presence of severe pain,
violaceous blisters or bullae, and petechiae or
ecchymoses, if widespread or associated with
systemic toxicity, may signal a deeper infection
such as necrotizing fasciitis [3, 12, 13].
The etiologic agent of cellulitis is believed to
be streptococci or Staphylococcus aureus in most
cases but can vary depending on extenuating
factors. These extenuating factors include
physical activities, trauma, water contact,
injection drug use or abuse and animal, insect,
or human bites. Cellulitis that is diffuse or
unassociated with a defined portal is believed to
be caused by Streptococcus species [3, 12–16].
The general term cellulitis has also been
applied to several diffuse spreading skin
infections. Some of these do not meet the
IDSA Guidelines definition. When used as a
general term, the word cellulitis is usually
preceded by some type of adjective such as
purulent, suppurative, non-purulent, non-
suppurative, necrotizing, synergistic
necrotizing, periorbital, buccal, and perianal.
Other forms of ‘‘cellulitis’’ are followed by
‘‘with’’ and a noun. These include cellulitis
with abscess, cellulitis with drainage, and
cellulitis with ulcer [12, 16, 17].
Several of these descriptors really point to a
much more complex infection than cellulitis.
Suppurative or purulent cellulitis indicates the
presence of pus in the form of an exudate and in
the absence of a drainable abscess. Non-
suppurative or non-purulent cellulitis indicates
the absence of both an exudate and abscess.
Erysipelas is another skin and soft-tissue
infection commonly classified as cellulitis but
is more superficial affecting the upper dermis.
Although both infections are generally similar
in surface appearance, the border of erysipelas is
sharply demarcated and raised whereas the
border of cellulitis is diffuse and flush with
surrounding skin. Systemic effects as described
above may also occur with erysipelas. According
to some authors, erysipelas and cellulitis may
coexist at the same site making differentiation
difficult. Erysipelas also usually affects children
and the elderly whereas cellulitis occurs in all
age groups. The etiologic agent of erysipelas
is believed to be almost always streptococci
[3, 12, 15, 17].
Two outdated descriptors often applied to
skin and soft-tissue infections in general are
uncomplicated and complicated. No form of
cellulitis using the IDSA guideline definition
would be complicated. ICD-9 coding does not
always discriminate between these two
outdated descriptors. Complicated skin and
soft-tissue infections are considered infected
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burns, deep-tissue infections, major abscesses,
infected ulcers, and perirectal abscesses [18].
Some skin conditions mimic cellulitis and
have been referred to as ‘‘pseudo-cellulitis’’
[19]. These include allergic dermatitis, contact
dermatitis, thrombophlebitis and DVT,
panniculitis and erythema migrans.
PATHOGENESIS
AND MICROBIOLOGY
There is relatively little information in the
literature about the pathogenesis of cellulitis.
Most cases result from microbial invasion
through a breach in the skin. Lacerations,
bite or puncture wounds, scratches,
instrumentation (e.g., needles), pre-existing
skin conditions or infections (e.g., chicken
pox, impetigo, or ulcer), burns, and surgery are
more among the common portals of entry. In
many cases the skin breaks are not clinically
apparent [3, 13, 15]. Bacteremia may contribute
to some cases of cellulitis. The most common
site of infection is the lower extremities (up to
70–88% of cases) [3, 13, 14, 20]. Fissured
webbing of the toes from maceration,
dermatophyte infection, or inflammatory
dermatoses is believed to contribute in many
cases [3, 13, 15, 21].
A number of risk factors have been identified
for both initial and recurrent episodes of lower
extremity cellulitis. These include obesity,
chronic edema from venous insufficiency or
lymphatic obstruction, previous cellulitis,
saphenectomy, and skin barrier disruption
especially web toe intertrigo [3, 13, 15, 21–24].
Other putative factors include smoking, previous
surgery, and previous antibiotic use [22].
Edema is a major contributor to the
development of cellulitis by creating small,
unapparent breaks in the skin. Swollen
cutaneous surfaces are also taut, fragile, and
more easily disrupted with minor trauma than
normal skin. The role of lymphatic obstruction
may relate to the inability to clear the
pathogen. Venous insufficiency may also cause
‘‘venous eczema’’ or stasis dermatitis which
could disrupt the cutaneous barrier. More
obvious breaches in the form of stasis ulcers
are also possible. The role of obesity may be
difficult to separate from edema since the two
often go hand in hand. Adipose tissue, however,
can compress lymphatic channels and impair
lymphatic flow. Obesity may also increase skin
fragility and decrease hygiene levels [13].
Groups A, B, C, and G streptococci and
Staphylococcus aureus are considered to be the
most common etiologic agents of cellulitis [3,
13, 15, 16].
Depending on extenuating factors, other
microbes can cause cellulitis. These include
Vibrio and Aeromonas species associated with
exposure to marine and freshwater
environments, respectively, Pasteurella
multocida associated with carnivore (especially
cat) bites, Pseudomonas aeruginosa associated
with neutropenia, and Erysipelothrix
rhusiopathiae associated with the handling of
seafood or meat. Cryptococcus neoformans may
cause cellulitis in patients with defective cell-
mediated immunity [3, 13, 15, 16, 25].
Biopsy of skin with cellulitis has shown
dilated lymphatics and capillaries, marked
dermal edema, and primarily neutrophilic
infiltration, either diffusely within the dermis
or concentrated around vessels [13]. The
bacterial burden from central and peripheral
biopsy is usually low suggesting an exaggerated
inflammatory response to low concentrations of
microorganisms or possibly their export
products [26].
It has been suggested that exotoxins
elaborated by streptococci or staphylococci are
178 Infect Dis Ther (2013) 2:175–185
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really the primary mediators of inflammation.
This theory proposes that immune responses to
exotoxins are responsible for most of the tissue
effects seen in cellulitis as opposed to direct
cytotoxic effects of the exotoxins. In other
words, the exotoxin would function as a
superantigen [13, 27].
CULTURE ETIOLOGY
Most cases of cellulitis are not amenable to
identification of a pathogen [3, 7, 13, 15].
Microbiological cultures are usually negative
for the majority of cases in which cultures are
performed [8].
A study of quantitative cultures of biopsy
specimens from cutaneous cellulitis found that
only 28.5% and 18% of needle aspiration and
punch biopsy cultures were positive,
respectively [26].
Other studies have shown blood cultures
were even less likely to be positive with yields
\5% [28–30]. Slightly higher yields (up to
7–10%) have been reported for patients who
had not previously received antimicrobial
therapy [13]. As a result, cultures of non-
suppurative cellulitis are rarely formed, and
treatment is informed by expert guidelines and
clinical judgment.
Positive blood cultures are most commonly
associated with streptococci [12, 13, 15]. Needle
aspirations and punch biopsies are most
commonly associated with Staphylococcus
aureus. Other techniques for pathogen
identification such as serologic and antigen
studies either alone or in combination have
shown a high (about 70–88%) streptococcal
predominance. These include antistreptolysin
O (ASO), antideoxyribonuclease B (ADB), and
antihyaluronidase (AHT) studies and
immunofluorescent staining for streptococcal
antigens of groups A, C, D, and G in skin biopsy
specimens [13, 15].
The overall body of evidence suggests that
streptococci are the most common single
pathogen in cellulitis [3, 12, 13, 15]. These
bacteria may either cause or contribute to up to
75–90% of cases [13]. However, there are some
recent reports that continue to disagree with this
conclusion [9, 31]. Nevertheless, there seems to
be a general agreement that cases of suppurative
(or purulent) cellulitis and those associated with
penetrating trauma or injection drug use are
more likely to have a staphylococcal etiology
[12, 15]. Yet, surgical drainage for purulent
abscesses has long been the mainstay of
therapy for such infections, most of which
resolve without ancillary antimicrobial therapy
[32]. The role of empirical therapy in these
patients remains undetermined. Community-
associated MRSA (CAMRSA) is probably a minor
contributor to non-suppurative cases of cellulitis
if at all [12, 13].
Gunderson and Martinello conducted a
systematic review of bacteremias in cellulitis
and erysipelas, excluding reports of complicated
cases, such as abscess, chronic diabetic
infections and necrotizing infections [33].
Streptococcal species were the predominant
culture finding, with S. aureus accounting for
15% of positive culture results. Surprisingly,
Gram-negative bacteria accounted for as many
cases as S. aureus. S. aureus was noted at similar
rates in both erysipelas and cellulitis, at odds
with the idea that almost all erysipelas is
streptococcal.
A recent study reported that non-suppurative
cellulitis may not be significantly associated
with MRSA, even in areas where CAMRSA is
endemic. The authors based their conclusions
on the comparable low prevalence of nasal and
inguinal colonization with CAMRSA in patients
with cellulitis in comparison to population
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controls. The study was conducted in a region
where methicillin-resistant strains were the
dominant form of Staphylococcus aureus [18].
This finding is particularly important since
most cases of cellulitis not amenable to
routine culture are considered non-suppurative
[8, 12]. It also reinforces the recommendation
against empirical coverage for MRSA in non-
suppurative cellulitis [5].
STUDIES OF EMPIRICAL COVERAGE
FOR CELLULITIS
At least four trials have been published since the
release of the 2005 IDSA guidelines comparing
beta lactams to antimicrobial agents with
activity against CAMRSA in cases of outpatient
cellulitis [8, 31, 34]. Two studies [8, 34]
evaluated ‘‘uncomplicated cellulitis’’ defined as
non-purulent cellulitis or minimal purulence,
not associated with ulcers or other complex
lesions. Both trials excluded patients with
diabetes mellitus as well as those who were
immunocompromised. The third study
included diabetics (36%) as well as patients
with cellulitis with ulcer and cellulitis with
abscess [31].
The first trial by Madaras-Kelly et al. [34]
was published in 2008. This multicenter
retrospective cohort study evaluated 861
patients. Beta lactams were prescribed for 631
patients and included primarily cephalexin,
dicloxacillin, and amoxicillin–clavulanate.
Non-beta lactams with activity against
CAMRSA were prescribed for 230 patients and
included primarily clindamycin, trimethoprim–
sulfamethoxazole, and a fluoroquinolone
(gatifloxacin or ciprofloxacin). Failure rates
were 14.7 and 17.0% for the beta lactam and
non-beta lactam groups, respectively (OR 0.85;
95% CI 0.55–1.31). Failure rates in the non-beta
lactam group were highest for trimethoprim–
sulfamethoxazole (18.6%) and the
fluoroquinolones (24.2%). However, these
were not statistically significantly different in
comparison to other antimicrobial agents or the
beta lactam class. MRSA colonization was
reported [30 days prior to treatment in 4.3%
of the non-beta lactam patients and in only
1.4% of the beta lactam patients (p = 0.014).
This study included a few animal bites and 40%
had a defined portal of entry.
The second trial by Pallin was published in
2013 [8]. This randomized, double-blind,
multicenter study evaluated 146 patients (both
adults and children). Cephalexin (from 300 mg
QID to 1 g QID) plus placebo (control group)
was administered to half of the patients (73).
Cephalexin (same dose) plus trimethoprim–
sulfamethoxazole (from 40/200 mg QID to
160/800 mg QID) was given to the other half.
Clinical cure was achieved in 60 of 73 (82%)
patients in the control group and in 62 of 73
(85%) of the interventional group (95% CI
-9.3% to 15%; p = 0.66). Colonization data
was obtained from 142 patients. Three of 69
patients in the control group and 4 of 72 in the
intervention group were colonized with MRSA.
Colonization had no impact on outcomes
(p = 0.67) [8].
The third trial by Khawcharoenporn and Tice
[31] was published in 2010. This retrospective
cohort study evaluated 405 patients at a
teaching clinic of a tertiary hospital.
Cephalexin was prescribed for 180 patients.
Trimethoprim–sulfamethoxazole and
clindamycin were prescribed for 152 patients
and 40 patients, respectively. The remaining 33
patients received miscellaneous antimicrobial
agents including amoxicillin–clavulanate,
amoxicillin, dicloxacillin, tetracycline,
doxycycline, ciprofloxacin, moxifloxacin, and
180 Infect Dis Ther (2013) 2:175–185
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azithromycin. Forty-four percent of patients
had cellulitis with abscess, 36% had ‘‘simple
cellulitis’’ while the remainder had cellulitis
with ulcer. Two-thirds of the patients with
abscesses received incision and drainage. The
success rate for trimethoprim–sulfamethoxazole
was significantly higher than that for
cephalexin (91% vs. 74%; OR 3.38; 95% CI
1.79–6.39; p\0.001). The rate for clindamycin
was also higher than that for cephalexin but did
not reach statistical significance (85% vs. 74%;
OR = 1.96; 95% CI 0.79–4.80; p = 0.22).
According to the authors, ‘‘The higher success
rates of trimethoprim–sulfamethoxazole
compared with cephalexin were consistent
regardless of the presence of wound or abscess,
the severity of cellulitis, or whether drainage
was performed’’. MRSA grew from 72 of the 117
cultures of ulcers or abscesses collected from
129 patients. All 72 isolates were susceptible to
trimethoprim–sulfamethoxazole. Streptococci
grew from only 9 cultures [31].
A prospective trial by Jeng et al. [10] was
published in 2010 and evaluated 179 inpatients
with diffuse, non-culturable cellulitis. It
included infections on various regions of the
body with the exception of those involving
periorbital, perineal, and groin regions. Most
cases of cellulitis occurred on the lower
extremities. All patients were assessed for
streptococcal ASO and ADB antibodies. This
trial was designed to evaluate the efficacy of
beta lactams (primarily cefazolin 1 gm q 8 h)
without a comparator. One hundred and
sixteen of 121 (95.8%) evaluable patients
responded to therapy including 21/23 (91%)
without evidence of streptococcal infection.
Nearly 28% of the study patients had diabetes
mellitus. MRSA colonization was not evaluated.
Jenkins and associates retrospectively
reviewed discharged patients from a Denver
hospital for 2007 using ICD-9 coding data for
SSTIs [35]. The primary outcome of interest was
treatment failure. They noted that 85% of
patients with cellulitis received anti-MRSA
therapy, and nearly half were discharged on a
regimen of TMP/SMX. The failure rate for
cellulitis was 12%. Most patients were treated
with broad-spectrum antibacterial agents, and
for a median duration of nearly 2 weeks. The
authors suggested SSKI patients would be
appropriate for antimicrobial stewardship
programs.
Jenkins and associates [36] subsequently
developed a clinical practice guideline
(available as an eFigure in their article) to
standardize management of cellulitis and
cutaneous abscess at their hospital. Parenteral
vancomycin was suggested for empirical therapy,
along with alternatives to blood cultures.
Patients with a discharge diagnosis of cellulitis
or cutaneous abscess were compared for 1 year
prior to and following implementation of the
guideline. Blood culture use declined, as did the
use of imaging studies for cellulitis. Vancomycin
use increased while beta lactam/beta lactamase
inhibitor combinations decreased. On discharge,
doxycycline use increased while amoxicillin/
clavulanate use decreased. Median duration of
antibiotic use decreased from 13 to 10 days.




A double-blind randomized, controlled trial by
Thomas et al. [37] was published in 2013. This
multicenter study evaluated 274 patients with a
history of at least 2 previous cases of cellulitis of
the leg within the previous 3 years. One
hundred and thirty-six patients received
penicillin V 250 mg bid for 12 months while
Infect Dis Ther (2013) 2:175–185 181
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the remaining patients received placebo.
Participants were followed for 3 years. The
median times to recurrence were 626 and
532 days in the penicillin and placebo groups,
respectively. During the initial 12 months, 30 of
the 136 prophylaxis patients had recurrence of
cellulitis in comparison to 51 of the 138 placebo
patients (hazard ratio 0.55; 95% CI 0.35–0.86;
p = 0.01). Participants were excluded from the
trial if they had a prior history of leg ulcer or
trauma. Most had a history of edema and the
mean body mass index (BMI) was slightly [35.
Although diabetes mellitus was not an
exclusion criterion for the trial, the authors
did not report how many participants, if any,
had this disorder. Patients with a BMI[33, three
or more previous episodes of cellulitis, or edema
had a poorer response to therapy. The authors
speculated the penicillin dose may have been
too low for the participants with high BMIs [37].
SHOULD EMPIRICAL
ANTIMICROBIAL COVERAGE
FOR CELLULITIS INCLUDE AGENTS
WITH ACTIVITY AGAINST MRSA?
The question will likely be addressed with the new
IDSA guideline for skin and soft-tissue infections
in the fall of 2013. It is unlikely the current
recommendations will change substantially if at
all. Recent data has done more to reinforce these
as well as those in the 2011 MRSA guideline.
Therefore, for ‘‘non-suppurative cellulitis’’, it
appears that empirical coverage for MRSA may
not be warranted even in patients who are or were
previously colonized (with MRSA) at the time of
diagnosis, or in communities where rates of MRSA
are high. These infections are most likely due to
streptococci and coverage should focus on these
bacteria. Concerns have been raised in the
medical literature about empirical monotherapy
with either trimethoprim–sulfamethoxazole or
doxycycline in skin and soft-tissue infections.
The anti-streptococcal activity of trimethoprim–
sulfamethoxazole and doxycycline has been
described as ‘‘uncertain’’ [38].
Early data published at the time of FDA
approval in 1973 indicated a very low MIC of
0.05/1 mcg/ml for the trimethoprim and
sulfamethoxazole components, respectively
[39]. Despite the impressive in vitro data, a
randomized, double-blind study published in
1973 showed trimethoprim–sulfamethoxazole
was inferior to penicillin G in the treatment of
group A streptococcal pharyngitis and tonsillitis
[40]. A 1999 in vitro study by Kaplan of
Streptococcus pyogenes isolates was discontinued
early because of a high rate of resistance to
trimethoprim–sulfamethoxazole [41]. A recent
in vitro study evaluating trimethoprim–
sulfamethoxazole activity against Streptococcus
pyogenes showed susceptibility was dependent on
the media used for culture [42]. Contemporary
prospective clinical studies of trimethoprim–
sulfamethoxazole in monomicrobial, streptococcal
mediated skin and soft-tissue infections are non-
existent.
Current literature suggests monotherapy
with beta lactams would be appropriate
therapy for immunocompetent outpatients
with non-suppurative forms of cellulitis. It
may be reasonable to cover MRSA in patients
with suppurative cellulitis if the prevalence is
high in the community. However, should this
recommendation apply to cases of suppurative
cellulitis in patients with recent skin and soft-
tissue infections caused by MSSA? Recent
articles also suggest it may be reasonable to
limit coverage for diabetics with diffuse, non-
purulent cellulitis not associated with an ulcer
to monotherapy with beta lactams.
What about inpatients? The current IDSA
recommendations only suggest ‘‘consider’’
182 Infect Dis Ther (2013) 2:175–185
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MRSA coverage; they do not recommend it.
Should you consider empirically covering for
MRSA in inpatients with non-suppurative
cellulitis? The microbiological literature does
not indicate or even remotely suggest that most
common community-acquired pathogens
associated with inpatient cases are different
from outpatient. Unfortunately, this question
has also not been adequately addressed in terms
of clinical data. The prospective Jeng trial
evaluated inpatients and reported a high rate of
success for beta lactams but had no comparator.
Again, it may be reasonable to cover diffuse, non-
purulent cellulitis with beta lactams only. Could
diabetics with non-suppurative infection of the
lower extremities receive monotherapy with a
beta lactam? It may be reasonable for those
provided the skin is intact. Non-infected ulcers
are unlikely to be associated with a surrounding
cellulitis. The 2012 IDSA diabetic foot guidelines
did not address this situation [38].
The current (2005) practice guidelines for
management of SSTIs can be found at the IDSA
website [43].
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